Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer (2012)
Source: The New England Journal of Medicine. Unidade: FM
Subjects: NEOPLASIAS MAMÁRIAS (QUIMIOTERAPIA), PLACEBOS, ANTINEOPLÁSICOS, METÁSTASE NEOPLÁSICA, ANTICORPOS, CITOTOXICIDADE IMUNOLÓGICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BASELGA, José et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England Journal of Medicine, v. 366, n. 2, p. 109-119, 2012Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113216. Acesso em: 18 nov. 2024.APA
Baselga, J., Cortés, J., Kim, S. B., Im, S. -A., Hegg, R., Im, Y. -H., et al. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England Journal of Medicine, 366( 2), 109-119. doi:10.1056/NEJMoa1113216NLM
Baselga J, Cortés J, Kim SB, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer [Internet]. The New England Journal of Medicine. 2012 ; 366( 2): 109-119.[citado 2024 nov. 18 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113216Vancouver
Baselga J, Cortés J, Kim SB, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer [Internet]. The New England Journal of Medicine. 2012 ; 366( 2): 109-119.[citado 2024 nov. 18 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113216
